Menu
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Clinical Trial
Investor Centre
Welcome
Investor Fact Sheet
ASX Announcements
Reports
Annual Reports
Half Yearly Reports
Quarterly Reports
Top 20 Shareholders
Research Reports
Shareholder Services
Investor FAQs
US Shareholders
Investor Newsletters
Communication
In the News
Presentations
Contact Us
Contact Us
Email Alerts
In the news
Recent Posts
Bulls ‘n Bears interview with Dr Chris Burns
Tumour Response in Sixth Patient Triggers Additional Recruitment in Pancreatic Cancer Trial
FDA Fast Track Designation Granted to Narmafotinib in Pancreatic Cancer
Investor Newsletter | September 2024
Proactive Investors | Interview with Amplia CEO Chris Burns on clinical trial progress
Fifth partial response confirmed in ACCENT trial
Categories
Archive
Company News
Investor Newsletters
Videos
18 Aug 2022
MEDIA RELEASE | Australian-made treatment for pancreatic cancer – clinical trial milestone
Read More
02 Aug 2022
First patient recruited into ACCENT trial
Read More
28 Jul 2022
QUARTERLY REPORT & 4C
Read More
23 Jun 2022
Navigating human research ethics
Read More
19 Apr 2022
QUARTERLY ACTIVITIES REPORT & 4C
Read More
30 Mar 2022
Amplia is hiring
Read More
17 Feb 2022
Improving Pancreatic Cancer Survival Rates
Read More
11 Feb 2022
WOMEN IN SCIENCE | Rhiannon Jones, Director, Operations
Read More
24 Jan 2022
Quarterly Report & 4C
Read More
02 Dec 2021
$2.1M R&D Cash Flow Loan
Read More
17 Nov 2021
New Phase 1 Clinical Trial Data
Read More
08 Nov 2021
$12.4m Capital Raise
Read More
26 Oct 2021
Amplia appoints leading drug developer as Oncology Clinical Advisor
Read More
30 Sep 2021
New FAK research published in Science Advances
Read More
27 Sep 2021
Proactive Lifesciences Webinar
Read More
26 Jul 2021
Amplia Therapeutics develops new approach to treat cancer and fibrosis
Read More
1
2
3